Literature DB >> 28884346

Quality of randomized controlled trials published in the International Urogynecology Journal 2007-2016.

Kyu Shik Kim1, Jae Hoon Chung1, Jung Ki Jo1, Jae Heon Kim2, Seungjun Kim3, Jeoung Man Cho4, Hee Ju Cho4, Hong Yong Choi1, Seung Wook Lee5,6.   

Abstract

INTRODUCTION AND HYPOTHESIS: Randomized controlled trials (RCTs) provide the best quality clinical evidence. The aim of this study was to assess the quality of RCTs published by the International Urogynecology Journal (IUJ) in 2007-2016.
METHODS: RCTs in original articles were extracted from PubMed and IUJ homepage. Change in RCT quality over time was assessed with Jadad and van Tulder scales and Cochrane Collaboration's risk of bias tool (CCRBT). Jadad scores of 3-5 or van Tulder scores of >5 indicated high-quality RCTs. The effect on RCT quality of including funding source and institutional review board (IRB) approval statements and describing the intervention was assessed. In addition, changes in RCT topics over time were assessed.
RESULTS: Annual RCT frequencies did not change significantly (6.7-15.7%): 36.1% and 25.7% described blinding and allocation concealment, respectively. Both tended to increase between 2013 and 2016, particularly 2013 and 2014. Funding statement inclusion (39.1% overall) and intervention description (78.2% overall) tended to increase steadily. IRB statement inclusion (60.4% overall) increased significantly (p < 0.01). Jadad scores and van Tulder rose significantly until 2014 (p < 0.01). Frequencies of high-quality RCTs tended to rise. CCRBT indicated that RCTs with a low risk of bias tended to increase until 2014. However, from 2015, Jadad scores, van Tulder, and CCRBT the low risk tended to decreased. RCTs with funding and IRB approval statements had higher Jadad and van Tulder scores than unfunded RCTs (p < 0.01 and p < 0.01, respectively). Intervention description did not associate with better quality.
CONCLUSIONS: RCT quality improved over time, but a dip in quality was observed in 2015-2016 because of decreased blinding and allocation concealment.

Keywords:  CONSORT statement; Randomized controlled trial; Reporting quality

Mesh:

Year:  2017        PMID: 28884346     DOI: 10.1007/s00192-017-3465-6

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  19 in total

Review 1.  Systematic reviews in health care: Assessing the quality of controlled clinical trials.

Authors:  P Jüni; D G Altman; M Egger
Journal:  BMJ       Date:  2001-07-07

Review 2.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Authors:  David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman
Journal:  Int J Surg       Date:  2011-10-12       Impact factor: 6.071

3.  Endorsement of the CONSORT statement by high impact medical journals: survey of instructions for authors.

Authors:  Douglas G Altman
Journal:  BMJ       Date:  2005-05-07

Review 4.  Evaluating the evidence: statistical methods in randomized controlled trials in the urological literature.

Authors:  Charles D Scales; Regina D Norris; Glenn M Preminger; Johannes Vieweg; Bercedis L Peterson; Philipp Dahm
Journal:  J Urol       Date:  2008-08-16       Impact factor: 7.450

Review 5.  Scales to assess the quality of randomized controlled trials: a systematic review.

Authors:  Susan Armijo Olivo; Luciana Gazzi Macedo; Inae Caroline Gadotti; Jorge Fuentes; Tasha Stanton; David J Magee
Journal:  Phys Ther       Date:  2007-12-11

6.  Improving the quality of reporting of randomized controlled trials. The CONSORT statement.

Authors:  C Begg; M Cho; S Eastwood; R Horton; D Moher; I Olkin; R Pitkin; D Rennie; K F Schulz; D Simel; D F Stroup
Journal:  JAMA       Date:  1996-08-28       Impact factor: 56.272

7.  Evidence based medicine: what it is and what it isn't.

Authors:  D L Sackett; W M Rosenberg; J A Gray; R B Haynes; W S Richardson
Journal:  BMJ       Date:  1996-01-13

8.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.

Authors:  K F Schulz; I Chalmers; R J Hayes; D G Altman
Journal:  JAMA       Date:  1995-02-01       Impact factor: 56.272

9.  Bias in treatment assignment in controlled clinical trials.

Authors:  T C Chalmers; P Celano; H S Sacks; H Smith
Journal:  N Engl J Med       Date:  1983-12-01       Impact factor: 91.245

10.  Funding source, trial outcome and reporting quality: are they related? Results of a pilot study.

Authors:  Tammy J Clifford; Nicholas J Barrowman; David Moher
Journal:  BMC Health Serv Res       Date:  2002-09-04       Impact factor: 2.655

View more
  3 in total

1.  Methodological and ethical quality of surgical trials from 2016 to 2020.

Authors:  Eloise Papet; Grégoire Moutel; Jean Pinson; Matthieu Monge; Edouard Roussel; Tom Teniere; Jean-Jacques Tuech; Valérie Bridoux
Journal:  Langenbecks Arch Surg       Date:  2022-08-27       Impact factor: 2.895

2.  Quality of evidence in a post-Soviet country: evaluation of methodological quality of controlled clinical trials published in national journals from Uzbekistan.

Authors:  Timur Aripov; Dilfuza Aniyozova; Irina Gorbunova
Journal:  BMC Med Res Methodol       Date:  2020-07-13       Impact factor: 4.615

3.  Quality Assessment and Relevant Clinical Impact of Randomized Controlled Trials of Varicocele: Next Step to Good-Quality Randomized Controlled Trial of Varicocele Treatment.

Authors:  Kyu Shik Kim; Jae Hoon Chung; Hyung Joon Park; Woo Jong Shin; Bum Hyun Lee; Seung Wook Lee
Journal:  World J Mens Health       Date:  2021-06-01       Impact factor: 5.400

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.